-+ 0.00%
-+ 0.00%
-+ 0.00%

B of A Securities Maintains Underperform on TG Therapeutics, Raises Price Target to $20

Benzinga·07/07/2026 14:24:20
Listen to the news
B of A Securities analyst Alec Stranahan maintains TG Therapeutics (NASDAQ:TGTX) with a Underperform and raises the price target from $17 to $20.